Marinus Pharmaceuticals, Inc. - News Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC . . . Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders The Company’s product, ZTALMY ® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U S in 2022
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and . . . Marinus has decided to complete enrollment in the RAISE trial at approximately 100 patients with topline results expected in the summer of 2024 Those results will be used to determine whether to continue development of IV ganaxolone
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial . . . Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders The Company’s product, ZTALMY ® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U S in 2022